1. Introduction
===============

Lung cancer is the leading cause of cancer-related death worldwide, with a dismal 5-year survival rate of 15% in men and 21% in women, according to the American Cancer Society.^\[[@R1]\]^ Over the last two decades, progress has been made in understanding the genetic and molecular basis of lung cancer in the hope that a genotype-driven targeted treatment approach to lung cancer will improve the survival and quality of life of patients with lung cancer.^\[[@R2]--[@R5]\]^ These new targeted therapies are efficacious and selective in their action. Consequently, it is now standard clinical practice to genotype advanced nonsmall cell lung cancer (NSCLC) at the time of diagnosis to help choose the best therapy.^\[[@R2]\]^

Early initiation of targeted therapies is associated with improved outcome, prolonged progression-free survival, and lower loco-regional recurrence rates but they should not be considered until tumor histology and molecular genetic analysis have been confirmed.^\[[@R5],[@R6]\]^ The National Comprehensive Cancer Network (NCCN) has described clinical practice guidelines for molecular genetic analysis for which there are FDA-approved targeted therapies.^\[[@R7]\]^ Though genotyping is essential for choosing the best treatment, there are barriers in some practice settings such as ability to get sufficient tissue for testing, cost of genotyping, and turn-around time to receive the genotyping results.

A noninvasive technique to obtain information regarding histology and mutations associated with NSCLC could be transformative for enabling targeted therapy, primarily if the technique can be used as an adjunct to a commonly used imaging technique such as CT. Recent publications have highlighted the role of radiomics in various malignancies including lung cancer.^\[[@R8]--[@R18]\]^ Radiomics involves histogram-based analyses of distribution and spatial variation of pixel values within a region of interest (ROI) to obtain information about tumor heterogeneity. Few published studies have evaluated the role of radiomics in predicting epidermal growth factor receptor (EGFR) mutation in adenocarcinoma, the most common mutation that has an approved targeted therapy as a first-line treatment. To the best of our knowledge, there are no publications on the incremental value of radiomics when combined with clinical history and standard imaging features. The purpose of our study was therefore to assess if radiomics can distinguish lung cancers based on histology and EGFR genetic mutations.

2. Materials and methods
========================

The Human Research Committee of our institutional review board approved the study. The study was compliant with the Health Insurance Portability and Accountability Act (HIPAA). Two studies of co-authors (LVS, MKK) have received research grants or consultation fee for unrelated projects. None of the other authors have any financial conflict of interest concerning the study.

2.1. Patients
-------------

Our retrospective study included patients with NSCLC who had known histologic diagnosis and genotyping analysis of at least EGFR between January 2008 and December 2013. Patients were identified from a lung cancer database managed by our Medical Thoracic Oncology Program registry. Patients with histologic subtypes other than adenocarcinoma and squamous cell carcinoma (such as those with small cell and large cell lung cancer and metastatic cancers from nonlung primary sites) were excluded (Fig. [1](#F1){ref-type="fig"}). We included 93 patients with nonsmall lung cancer (total 94 lung nodules/masses: 69 adenocarcinomas and 25 squamous cell carcinoma). Out of 69 adenocarcinomas, 25 were EGFR mutation positive and the remaining 44 were EGFR wild-type. The mean age of patients was 60 ± 11 years (range: 26--96 years). There were 43 men and 50 women (Table [1](#T1){ref-type="table"}). The tissue diagnosis of NSCLC was established with mediastinoscopy, bronchoscopy, or CT-guided biopsy of primary or metastatic sites. All biopsy specimens were tested for EGFR mutations by multiplex PCR-based assay (Snapshot; Applied Biosystems, Foster City, CA). The smoking history was gathered from electronic medical records and was classified as current, former, and never smokers.

![CONSORT diagram of patient selection.](medi-98-e13963-g001){#F1}
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Patient demographics.
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2.2. CT scanning
----------------

The CT examinations were performed at a single hospital but on multiple different CT scanners (8, 16, 64, and 128- slice multidetector-row CT). All included CT examinations represented contrast-enhanced CT performed using helical acquisition mode, 100--120 kV, automatic exposure control, reconstructed slice thickness of 2.5 to 3 mm and standard soft tissue reconstruction kernel. Only transverse CT images were used for CT texture analysis.

Analyzed images included one chest CT examination per eligible patient performed before any therapy (surgery, radiation, or systemic therapy). In patients with multiple potential imaging studies, the examination closest to the date of tissue sampling was selected. The images were evaluated on PACS system (Impax, software version 6.5, Agfa Healthcare) by fellowship trained thoracic radiologist (SRD, 17 years of experience). The size was recorded in two dimensions: the longest diameter (LD) and longest perpendicular diameter (LPD). The density of the lung lesion was characterized as solid, ground glass, and part solid nodule based on Fleischner society guidelines of thoracic radiology nomenclature.

2.3. Radiomics
--------------

DICOM images from CT examinations were imported to a secure offline server for radiomics analysis with commercially available software (TexRAD limited, UK). For each CT examination, a radiologist co-investigator (RLG) identified the transverse image with the maximal dimension of the malignant lung nodule or mass. This co-investigator (RLG) was blinded to the results of the histology and molecular genetic testing. If a motion, contrast streaking or beam hardening artifacts were noted on the image with maximal dimension, another "artifact-free" image demonstrating the lesion was chosen. The longest and its orthogonal dimensions were measured for each lesion on the image used for radiomics. A ROI was carefully drawn in the nodule or mass avoiding contact with its edges using a semi-automated process (Fig. [2](#F2){ref-type="fig"}). All lesions in the pleura, chest wall, mediastinum, and bones were excluded. For cavitary lesions, a threshold of greater than or equal to −50HU was applied to exclude air component and include only the solid portions of the lesions. Macroscopic calcifications if any were also excluded from the ROI.

![Segmentation of tumor by outlining the region of interest for extracting radiomic features.](medi-98-e13963-g003){#F2}

The radiomic analysis comprised an initial image filtration step followed by quantification of texture within the lesion. The software highlights the size of the image features with the spatial scaling factor (SSF), which ranges between object radii of 0, 2, 3, 4, 5, and 6 mm. The filtration step is important to remove image heterogeneity that is due to photon noise and to highlight biologically important heterogeneity.^\[[@R8],[@R10]\]^

2.4. Quantitative analysis
--------------------------

The following features were analyzed using the CTTA software. The mean value of pixels with in a ROI as mean Hounsfield unit (HU) values. The degree of dispersion of the HU value is expressed as standard deviation (SD). The SD was also expressed as logarithmic expression as "normalized SD": ln(SD)/ln(*n*) \[= ln(SD)/ln (total pixels in ROI)\] to represent the variability of region size. The number of pixels having positive value are expressed as percent positive pixels (PPP), and the mean positive pixels (MPP) indicates value greater than 0. The asymmetry of histogram is expressed as skewness, which can be negative or positive. The peak of distribution in histogram represents kurtosis and is a marker of vascularity and angiogenesis in the tumor. The kurtosis can be positive with peak greater than normal Gaussian distribution and negative with smaller peak. The complexity or heterogeneity of the structure is represented by entropy. The vascular structures are represented by kurtosis and distribution of nonvascular structures by skewness. The software enables selection of SSFs (0, 2, 3, 4, 5, 6) based on the lesion size to alter the filtration threshold.

2.5. Statistical analysis
-------------------------

The data were analyzed using SPSS 21 statistical software (IBM, Armonk, NY). A Pearson correlation analysis was performed to compare the radiomics features, clinical history (age, gender, and smoking) and standard imaging features among different cancer types (adenocarcinoma vs squamous cell carcinoma, EGFR positive vs EGFR wild-type). The *P*-value of less than or equal to 0.05 with a 95% confidence interval was considered significant. Receiver operating characteristic (ROC) curves and area under curve (AUC) were generated for various radiomic features. The probability variables for each group and all group together were derived from the binary logistic regression analysis. The ROC curves were generated for these probability variables to see the difference.

3. Results
==========

3.1. Differentiating adenocarcinoma vs squamous cell carcinoma
--------------------------------------------------------------

Pearson correlation analysis showed that there were significant correlations for 4/11 radiomics features (entropy, log of SD, normalized SD, total), 2/3 clinical (smoking, gender), and 1/3 imaging features (LD) among adenocarcinomas and squamous cell carcinomas (*r* = −0.354--0.112, n = 94, *P* = .033 to \<.0001). The separate ROC analysis showed that 3/11 radiomic features \[AUC 0.686--0.744, *P* = .006 to \<.0001\], 1/3 clinical features (smoking) (AUC 0.732, *P* = .001), and 2/3 imaging features (LD and LPD) \[AUC 0.646--0658, *P* = .020 to .032\] were significantly different. The entropy was the only predictor on logistic regression (*P* = .015, Nagelkerke *R*^2^ = 0.30). The entropy explained the 30% variance and correctly identified 79.0% carcinomas. After adding all major clinical, imaging and radiomics features in the regression model, the entropy (*P* = .030), gender (*P* = .049), and smoking (*P* = .007) were the predictors (Nagelkerke *R*^2^ = 0.57). The entropy, gender, and smoking explained the 57% variance and correctly identified 85.0% carcinomas.

The separate ROC analysis (for radiomics, clinical, imaging) showed that 3/11 radiomic features (entropy, normalized SD, total) \[AUC 0.686--0.744 (0.545--0.859), *P* = .006 to \<0.0001\], 1/3 clinical features (smoking) \[AUC 0.732 (0.633--0.831), *P* = .001\], and 2/3 imaging features (LD and LPD) \[AUC 0.646--0658 (0.508--0.795), *P* = .020 to 0.032\] were significantly different between the adenocarcinomas and squamous cell carcinomas (Table [2](#T2){ref-type="table"}).

###### 

AUC values for radiomic features for adenocarcinoma vs squamous cell carcinoma.
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For probability variables (radiomics, clinical, imaging), ROC analysis showed higher AUC value for radiomics (AUC 0.800, *P* \< .0001) than clinical (AUC 0.780, *P* \< .0001) and imaging (AUC 0.694, *P* = .004) for differentiating adenocarcinomas and squamous cell carcinomas (Fig. [3](#F3){ref-type="fig"}). There was a significant difference among radiomics and imaging probability variables (*P* \< .0001), and no difference among radiomics and clinical features (*P* = .13). The AUC value for combined (radiomics, clinical, imaging) probability variable was significantly higher (AUC 0.923, *P* \< .0001) than separate probability variables.

![Receiver operating characteristic curves with AUC values for probability variables radiomics, clinical, imaging and combined differentiate adenocarcinomas and squamous cell carcinomas of the lung. The AUC value for combined (radiomics, clinical, imaging) probability variable was improved (AUC 0.923, *P* \< .0001) and higher than separate probability variables. AUC = area under curve.](medi-98-e13963-g005){#F3}

3.2. Differentiating EGFR mutant vs EGFR wild-type adenocarcinoma
-----------------------------------------------------------------

ROC analyses (for radiomics, clinical, imaging) showed that 2/11 radiomic features (kurtosis, K2) \[AUC 0.656--0.713 (0.522--0.845), *P* = .03 to .003\], 1/3 clinical features (smoking) \[AUC 0.758 (0.638--0.878), *P* \< .0001\] (Fig. [4](#F4){ref-type="fig"}, Table [3](#T3){ref-type="table"}), and none of the imaging features were significantly different between EGFR mutant and EGFR wild-type adenocarcinomas. The kurtosis was the only predictor for differentiating FGFR positive and EGFR wild-type adenocarcinomas on logistic regression analysis (*P* = .037, Nagelkerke *R*^2^ = 0.15). The kurtosis explained the 15% variance and correctly identified 70.0% carcinomas.

![Receiver operating characteristic curves with AUC values for probability variables radiomics, clinical, imaging and combined differentiate fibroblast growth factor receptor positive and epidermal growth factor receptor wild-type adenocarcinomas of the lung. The AUC value for combined (radiomics, clinical, imaging) probability variable was improved (AUC 0.863, *P* \< .0001) and higher than separate probability variables. AUC = area under curve.](medi-98-e13963-g006){#F4}
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AUC values for radiomic features for EGFR mutant vs EGFR wild type adenocarcinoma.
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For probability variables (radiomics, clinical, imaging), ROC analysis showed slightly higher AUC value for clinical (AUC 0.794, *P* \< .0001) than radiomics (AUC 0.725, *P* = .002) and significantly higher than standard imaging (AUC 0.553, *P* = .461). The AUC value for combined (radiomics, clinical, imaging) probability variable was significantly higher (AUC 0.863, *P* \< .0001) than separate probability variables.

3.3. Differentiating EGFR wild-type adenocarcinoma vs squamous cell carcinoma
-----------------------------------------------------------------------------

The separate ROC analysis (for radiomics, clinical, imaging) showed that only 3/11 radiomic features (entropy, normalized SD, total) \[AUC 0.673--0.759 (0.532--0.879), *P* = .018 to \<.0001\], 1/3 of the clinical features, and 2/3 imaging features (LP and LPD) \[AUC 0.652--667 (0.513--0.804), *P* = .039 to .023\] were significantly different (Table [4](#T4){ref-type="table"}).
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AUC values for radiomic features for EGFR wild type adenocarcinoma vs squamous cell carcinoma.
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For probability variables (radiomics, clinical, imaging), ROC analysis showed higher AUC value for radiomics (AUC 0.800, *P* \< .0001) than clinical (AUC 0.676, *P* = .017) and standard imaging (AUC 0.708, *P* \< .0001) for differentiating EGFR wild-type adenocarcinoma and squamous cell carcinomas. The AUC value for combined (radiomics, clinical, imaging) probability variable was significantly higher (AUC 0.890, *P* \< .0001) than separate probability variables.

3.4. Differentiating EGFR mutant adenocarcinoma vs squamous cell carcinoma
--------------------------------------------------------------------------

ROC analyses (for radiomics, clinical, imaging) showed that 6/11 radiomic features (entropy, kurtosis, log of SD, normalized SD, total, K2) \[AUC 0.664--0.721 (0.505--0.862), *P* = .011 to \<.0001\], 2/3 clinical features (smoking, gender) \[AUC 0.672--0.889 (0.523--0.987), *P* = .034 to \<.0001\], and none of the imaging features were significantly different between the two groups.

ROC analysis for probability variables (radiomics, clinical, imaging) showed higher AUC value for clinical (most squamous cell carcinomas patients were male smokers and most EGFR mutant patients were female nonsmokers) (AUC 0.936, *P* \< .0001) than radiomics (AUC 0.815, *P* \< .0001) and imaging (AUC 0.666, *P* = .040) for differentiating EGFR mutant adenocarcinoma and squamous cell carcinomas (Table [5](#T5){ref-type="table"}). The AUC value for combined (radiomics, clinical, imaging) probability variable was close to 1 (*P* \< .0001) and significantly higher than independent probability variables.
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AUC values for radiomic features for EGFR mutation adenocarcinoma vs squamous cell carcinoma.
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4. Discussion
=============

Recent studies on value of radiomics for predicting histopathology have not considered the significance of clinical history and imaging features which may have overemphasized the significance of radiomics.^\[[@R19]--[@R21]\]^ We found that accuracy for radiomics features (AUC 0.800) was higher than clinical (AUC 0.780) and standard imaging (AUC 0.694) in differentiating adenocarcinoma from squamous cell carcinomas. After combining radiomics, clinical, and imaging features, the accuracy increased (AUC 0.923). Similar accuracy has been reported with few previous studies as well.^\[[@R22]--[@R33]\]^ This is important due to increased overall incidence of adenocarcinoma and those in the central locations.^\[[@R31]\]^ The radiomics (entropy) along with clinical (smoking and gender) and imaging features can correctly identify 85% adenocarcinoma and squamous cell carcinomas. This predictive value is even higher between EGFR mutant adenocarcinoma and squamous cell carcinomas, where the accuracy reaches up to 95%. This is mainly due to the fact that most squamous cell carcinomas patients were male smokers and most EGFR mutant patients were female nonsmokers. The combined radiomics (kurtosis), clinical (smoking), and imaging can correctly differentiate only up to 75% EGFR positive and EGFR wild-type adenocarcinoma. The relatively similar clinical features can partly explain the slightly decreased accuracy in this group, but even in this cohort addition of radiomics improved the accuracy of detection. In our study, none of the imaging features (density and size of the tumor) was a predictor for predicting the mutation status.

Weiss et al have reported that radiomics can differentiate NSCLC with KRAS mutation from pan-wildtype.^\[[@R30]\]^ Our study demonstrates that radiomics features can detect differences in tumor heterogeneity (kurtosis and entropy) between adenocarcinomas with and without EGFR mutations and between adenocarcinomas and squamous cell carcinoma. The accuracy of differentiating these carcinomas improved with combining radiomics features along with clinical and imaging features noted in our study. Mak and Digumarthy et al reported lower 18F-fluorodeoxyglucose (FDG) uptake on PET examinations in patients with EGFR-positive adenocarcinoma compared to those with EGFR wild-type.^\[[@R32]\]^ This supports observation from our study that lesions with higher tumor heterogeneity (entropy) have higher metabolic activity with greater 18-FDG uptake. Future studies will be needed to assess if radiomics in combination with the 18-FDG PET can enable better identification of EGFR mutation in patients with adenocarcinoma.

There was a significant difference in kurtosis between EGFR mutant and wild-type adenocarcinoma. Kurtosis is a marker for tumor angiogenesis, which in turn is an essential factor determining tumor aggressiveness and overall survival. Recent studies have reported improved survival upon addition of antiangiogenic therapy to patients with EGFR mutant adenocarcinomas receiving erlotinib.^\[[@R27]\]^ This implies that as a surrogate marker of tumor angiogenesis, kurtosis might be useful in predicting and assessing response to antiangiogenic treatment in patients with EGFR mutant adenocarcinomas.

Implication of our study is that by integrating clinical and imaging features with radiomics features can improve the distinction of tumors with squamous and adenocarcinoma histology and EGFR mutation. There are established guidelines for genetic testing for EGFR mutations and ALK rearrangements in patients with lung adenocarcinomas^\[[@R7]\]^ but issues related to cost, invasiveness, and logistics of genetic profiling are not trivial. In this context, our study demonstrates that differentiation of lung cancer based on histology and/or presence of EGFR positive with noninvasive technique such as radiomics could assist the multidisciplinary lung cancer treatment team in the decision making regarding molecular testing options by triaging patients with lung cancer, separating them based on histology and likelihood of presence of mutation, in addition to other predictors of presence of genetic mutation such as smoking history and ethnicity. This could potentially affect therapy selection for patients with cancer and would allow the pathologist to standardize genetic profiling, prioritizing tests, saving tissues from biopsy sample allowing for a more thoughtful use of time, available sampled tissue and test and labor-related expenses. Although less likely in the developed nations, tools such as radiomics could be helpful in nations with limited resources. Indeed, such a cost-effective model based on radiomics has been reported for colorectal cancer surveillance^\[[@R34]\]^ and in chemotherapy selection for patients with NSCLC.^\[[@R35]\]^

Our study has limitations. Since this was a retrospective study, we did not perform sample size estimation. However, our study has a higher sample size compared to some other publications on radiomics. Ng et al have reported that measurement of radiomics over the entire tumor volume is more accurate than from a single image with largest axial dimensions (as in our study) since the former better represents tumor heterogeneity and has a stronger correlation with overall survival compared to a single slice analysis.^\[[@R36]\]^ However, most investigations have reported promising results for assessment of tumor biology^\[[@R37],[@R38]\]^ and prognosis^\[[@R24],[@R39]\]^ with radiomics from a single image with the largest cross-sectional tumor area. Another limitation of our study involves the exclusion of other histological types of primary and metastatic lung cancers. We also did not assess the effect of different forms of treatment on radiomics since all post-treatment CT examinations were excluded from our study.

In conclusion, radiomics features of NSCLC can help distinguish between adenocarcinoma and squamous cell carcinoma and EGFR positive and wild-type adenocarcinomas. Entropy and Kurtosis are the two most important distinguishing radiomic features. The radiomics evaluation adds incremental value to clinical history and standard imaging features in predicting histology and EGFR mutations and therefore, incorporating radiomics in CT evaluation of nonsmall lung cancers has potential clinical application.
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